Literature DB >> 23401227

LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma.

Jacky T Yeung1, Ronald L Hamilton, Koji Ohnishi, Maki Ikeura, Douglas M Potter, Marina N Nikiforova, Soldano Ferrone, Regina I Jakacki, Ian F Pollack, Hideho Okada.   

Abstract

PURPOSE: Glioblastoma (GBM) shows downregulated expression of human leukocyte antigen (HLA) class I, thereby escaping from cytotoxic T cells and limiting the efficacy of immunotherapy. Loss of heterozygosity (LOH) of HLA class I (6p21) and/or β-2 microglobulin (B2m) (15q21) regions represents irreversible downregulation. In this study, we examined the prevalence of these LOH events and their relations with overall survival in GBM. EXPERIMENTAL
DESIGN: In a cross-sectional analysis on 60 adult patients with GBM, DNA from formalin-fixed, paraffin-embedded specimens were evaluated for 10 microsatellite regions of HLA class I, B2m, HLA class II, HLA class III, and 6q by PCR as well as immunohistochemical evaluation of HLA class I expression and CD8(+) T-cell infiltration.
RESULTS: LOH in HLA class I, B2m, HLA class II, HLA class III, and 6q regions was present in 41.4%, 18.2%, 9.4%, 77.8%, and 36.0% of informative cases, respectively. LOH of HLA class I was associated with shorter overall survival (HR = 4.89, P = 0.0078). HLA class I was downregulated in 22% to 43% of cases based on immunohistochemistry. Cases that displayed negative staining were significantly younger. HLA class I expression correlated with intratumoral CD8(+) T-cell infiltration.
CONCLUSION: LOH in the HLA class I region is frequent in adult GBMs. The association of shorter survival with LOH in this region suggests a crucial role for these genes in immunosurveillance. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23401227      PMCID: PMC3618546          DOI: 10.1158/1078-0432.CCR-12-2861

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  46 in total

1.  Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors.

Authors:  Angelica Facoetti; Rosanna Nano; Paola Zelini; Patrizia Morbini; Eugenio Benericetti; Mauro Ceroni; Michael Campoli; Soldano Ferrone
Journal:  Clin Cancer Res       Date:  2005-12-01       Impact factor: 12.531

2.  Reduced expression of the transporter associated with antigen processing 1 molecule in malignant glioma cells, and its restoration by interferon-gamma and -beta.

Authors:  Eiji Satoh; Tadashi Mabuchi; Hiroki Satoh; Takayuki Asahara; Hideaki Nukui; Hirofumi Naganuma
Journal:  J Neurosurg       Date:  2006-02       Impact factor: 5.115

3.  LOH at 6p21.3 region and HLA class I altered phenotypes in bladder carcinomas.

Authors:  Isabel Maleno; Jose Maria Romero; Teresa Cabrera; Laura Paco; Natalia Aptsiauri; Jose Manuel Cozar; Miguel Tallada; Miguel Angel López-Nevot; Federico Garrido
Journal:  Immunogenetics       Date:  2006-05-17       Impact factor: 2.846

4.  HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas.

Authors:  M Feenstra; M Veltkamp; J van Kuik; S Wiertsema; P Slootweg; J van den Tweel; R de Weger; M Tilanus
Journal:  Tissue Antigens       Date:  1999-09

5.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

Review 6.  Molecular pathological approaches to human tumor immunology.

Authors:  Noriyuki Sato; Yoshihiko Hirohashi; Tomohide Tsukahara; Tomoki Kikuchi; Hiroeki Sahara; Kenjiro Kamiguchi; Shingo Ichimiya; Yasuaki Tamura; Toshihiko Torigoe
Journal:  Pathol Int       Date:  2009-04       Impact factor: 2.534

7.  Prognostic significance of allelic losses in primary melanoma.

Authors:  E Healy; C Belgaid; M Takata; D Harrison; N W Zhu; D A Burd; H S Rigby; J N Matthews; J L Rees
Journal:  Oncogene       Date:  1998-04-30       Impact factor: 9.867

8.  Alterations of HLA class I expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity.

Authors:  Cristina Garrido; Ignacio Algarra; Isabel Maleno; Julia Stefanski; Antonia Collado; Federico Garrido; Angel M Garcia-Lora
Journal:  Cancer Immunol Immunother       Date:  2009-05-09       Impact factor: 6.968

Review 9.  The HLA genomic loci map: expression, interaction, diversity and disease.

Authors:  Takashi Shiina; Kazuyoshi Hosomichi; Hidetoshi Inoko; Jerzy K Kulski
Journal:  J Hum Genet       Date:  2009-01-09       Impact factor: 3.172

10.  Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma.

Authors:  Lizzia Raffaghello; Paolo Nozza; Fabio Morandi; Marta Camoriano; Xinhui Wang; Maria Luisa Garrè; Armando Cama; Giuseppe Basso; Soldano Ferrone; Claudio Gambini; Vito Pistoia
Journal:  Cancer Res       Date:  2007-06-01       Impact factor: 12.701

View more
  39 in total

1.  Poor survival after resection of early gastric cancer: extremes of survivorship analysis reveal distinct genomic profile.

Authors:  J Datta; E M Da Silva; C Kandoth; T Song; A E Russo; J M Hernandez; B S Taylor; Y Y Janjigian; L H Tang; D B Solit; V E Strong
Journal:  Br J Surg       Date:  2019-11-25       Impact factor: 6.939

Review 2.  Immunotherapy for High Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons.

Authors:  Jacob S Young; Fara Dayani; Ramin A Morshed; Hideho Okada; Manish K Aghi
Journal:  World Neurosurg       Date:  2019-01-21       Impact factor: 2.104

3.  Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.

Authors:  Tsubasa Miyazaki; Eiichi Ishikawa; Masahide Matsuda; Hiroyoshi Akutsu; Satoru Osuka; Noriaki Sakamoto; Shingo Takano; Tetsuya Yamamoto; Koji Tsuboi; Akira Matsumura
Journal:  J Neurooncol       Date:  2017-04-26       Impact factor: 4.130

4.  Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs).

Authors:  Lei Cai; Theodoros Michelakos; Vikram Deshpande; Kshitij S Arora; Teppei Yamada; David T Ting; Marty S Taylor; Carlos Fernandez-Del Castillo; Andrew L Warshaw; Keith D Lillemoe; Soldano Ferrone; Cristina R Ferrone
Journal:  Clin Cancer Res       Date:  2019-01-22       Impact factor: 12.531

5.  Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinoma.

Authors:  Kelly G Paulson; Andrew Tegeder; Christoph Willmes; Jayasri G Iyer; Olga K Afanasiev; David Schrama; Shinichi Koba; Renee Thibodeau; Kotaro Nagase; William T Simonson; Aaron Seo; David M Koelle; Margaret Madeleine; Shailender Bhatia; Hideki Nakajima; Shigetoshi Sano; James S Hardwick; Mary L Disis; Michele A Cleary; Jürgen C Becker; Paul Nghiem
Journal:  Cancer Immunol Res       Date:  2014-08-12       Impact factor: 11.151

6.  Human Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy.

Authors:  Bracha Shraibman; Dganit Melamed Kadosh; Eilon Barnea; Arie Admon
Journal:  Mol Cell Proteomics       Date:  2016-07-13       Impact factor: 5.911

Review 7.  Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors.

Authors:  Lorenzo Galluzzi; Juliette Humeau; Aitziber Buqué; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2020-08-05       Impact factor: 66.675

8.  T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.

Authors:  Karolina Woroniecka; Pakawat Chongsathidkiet; Kristen Rhodin; Hanna Kemeny; Cosette Dechant; S Harrison Farber; Aladine A Elsamadicy; Xiuyu Cui; Shohei Koyama; Christina Jackson; Landon J Hansen; Tanner M Johanns; Luis Sanchez-Perez; Vidyalakshmi Chandramohan; Yen-Rei Andrea Yu; Darell D Bigner; Amber Giles; Patrick Healy; Glenn Dranoff; Kent J Weinhold; Gavin P Dunn; Peter E Fecci
Journal:  Clin Cancer Res       Date:  2018-02-07       Impact factor: 12.531

Review 9.  Effective effectors: How T cells access and infiltrate the central nervous system.

Authors:  Kendra L Congdon; Luis A Sanchez-Perez; John H Sampson
Journal:  Pharmacol Ther       Date:  2018-12-14       Impact factor: 12.310

Review 10.  Immunotherapy for brain cancer: recent progress and future promise.

Authors:  Christopher M Jackson; Michael Lim; Charles G Drake
Journal:  Clin Cancer Res       Date:  2014-04-25       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.